Probiotic
Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
1. A method for treating a subject, the method comprising administering to the subject an oral formulation comprising isolated strain Bifidobacterium longum deposited with NCIMB under accession number NCIMB 41676, wherein the Bifidobacterium longum strain is in the form of a powder,
wherein the subject has a disorder chosen from an anxiety disorder, a mood disorder, or a behavioral disorder, and the formulation treats the disorder.
2. The method of claim 1 , wherein the formulation reduces stress of the subject.
3. The method of claim 1 , wherein the disorder is bipolar illness, depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, or post-traumatic disorder.
4. The method of claim 1 , wherein the subject is a human.
5. The method of claim 1 , wherein administration of the formulation is part of a regimen for replacing a selective serotonin reuptake inhibitor.
6. The method of claim 5 , wherein the selective serotonin reuptake inhibitor is escitalopram.
7. The method of claim 1 , wherein the formulation comprises an ingestible carrier.
8. The method of claim 7 , wherein the ingestible carrier comprises a dairy product.
9. The method of claim 7 , wherein the ingestible carrier comprises a dressing or a beverage.
10. The method of claim 1 , wherein the composition comprises more than 10 6 cfu of the Bifidobacterium longum strain per gram of the composition.
11. A method for treating a subject, the method comprising administering to the subject an oral formulation comprising isolated strain Bifidobacterium longum deposited with NCIMB under accession number NCIMB 41676 and an ingestible carrier,
wherein the subject has a disorder chosen from an anxiety disorder, a mood disorder, or a behavioral disorder, and the formulation treats the disorder.
12. The method of claim 11 , wherein each of the Bifidobacterium longum strain and the ingestible carrier is in the form of a powder, the formulation being administered in the form of a powder.
13. The method of claim 11 , wherein the formulation comprises more than 10 6 cfu of the Bifidobacterium longum strain per gram of the formulation.
14. The method of claim 11 , wherein the formulation is administered in the form of a food product or a beverage.
15. The method of claim 11 , wherein the formulation is administered in the form of a capsule or a tablet.
16. A method for treating a subject, the method comprising administering to the subject an oral formulation comprising isolated strain Bifidobacterium longum deposited with NCIMB under accession number NCIMB 41676 and an ingestible carrier, wherein the Bifidobacterium longum strain is in the form of a powder, wherein the formulation comprises more than 10 6 cfu per gram of the Bifidobacterium longum strain;
wherein the subject has a disorder chosen from an anxiety disorder, a mood disorder, or a behavioral disorder, and the formulation treats the disorder.
17. The method of claim 16 , wherein the formulation is administered in the form of a food product or a beverage.
18. The method of claim 16 , wherein the formulation reduces stress of the subject.